Forbes came out with a post that shows findings from a newly released article by the open access journals of MDPI (Molecular Diversity Preservation International) titled “Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer’s Disease Neurodegeneration”, support CBD’s potential as a promising intervention for addressing cognitive challenges related to learning and memory in mice with Alzheimer’s disease (AD).
The study proposes that CBD has the capacity to alleviate synaptic dysfunction and offer neuroprotection in mice induced with Aβ1–42, a distinctive feature of AD.
“Using GFAP to identify reactive astrocytes, we observed that CBD diminished their activation in Aβ-stimulated hippocampal regions (Figure 4E). Our findings suggest CBD’s efficacy in moderating microglial and astrocytic activation, offering anti-inflammatory benefits that protect synaptic function and alleviate AD-associated cognitive deficits. Our data support CBD’s potential therapeutic role in countering AD-related neuroinflammation.”
“Our research substantiates CBD’s efficacy in either preventing or mitigating the effects of AD. Thus, future formulations of CBD supplements might be strategically positioned to include indications for AD prevention and alleviation, expanding its therapeutic repertoire.”
The research delved into the possibility of CBD reducing this inflammation in mice treated with Aβ1–42 in vitro. The results demonstrated a significant reduction in inflammatory agents, diminished microglia activation, and alleviated astrocyte activation in critical brain regions affected by Aβ-stimulation due to CBD administration.
